BD (Becton, Dickinson and Company), a leading medical technology company, has announced the completion of its acquisition of Edwards Lifesciences’ Critical Care product group.
The $4.2bn all-cash transaction, announced in June 2024, will see the Critical Care product group being renamed as BD Advanced Patient Monitoring.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BD Advanced Patient Monitoring enhances BD’s smart connected care solutions with its portfolio of monitoring technologies, AI-enabled clinical decision tools, and a robust innovation pipeline. The technologies from BD Advanced Patient Monitoring are often used alongside the BD Alaris Infusion System in critical care settings such as operating rooms and intensive care units.
The integration of BD’s new monitoring and existing infusion platforms paves the way for future innovations in closed-loop haemodynamic monitoring and IV fluid and medication administration. This is made possible by integrating combined company data sets and interoperability capabilities.
The product line of BD Advanced Patient Monitoring includes the Swan Ganz pulmonary artery catheter, sensors, cuffs, tissue oximetry sensors, and monitors. These smart technologies utilise advanced data analytics, machine learning, and AI-based algorithms to aid clinicians in patient care decisions.
BD Advanced Patient Monitoring will be a distinct business unit within BD’s Medical segment, adhering to the company’s smart connected care strategy. The unit will continue to operate from Irvine, California.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEdwards’ former corporate vice president Katie Szyman has been appointed worldwide president of BD Advanced Patient Monitoring. She will report to Mike Garrison, executive vice president and president of the BD Medical segment.
The acquisition is expected to have a negligible effect on BD’s fiscal year 2024 guidance, as outlined in the 1 August third-quarter earnings news release.
